Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human α-galactosidase A: Pharmacological chaperoning efficacy on fabry disease mutants

ACS Chemical Biology

Volumn 9, Issue 7, 2014, Pages 1460-1469

  Yu, Yi ^a,b   Mena Barragán, Teresa ^c   Higaki, Katsumi ^a   Johnson, Jennifer L ^d   Drury, Jason E ^d   Lieberman, Raquel L ^d   Nakasone, Naoe ^b   Ninomiya, Haruaki ^b   Tsukimura, Takahiro ^e   Sakuraba, Hitoshi ^e   Suzuki, Yoshiyuki ^f   Nanba, Eiji ^a   Mellet, Carmen Ortiz ^c   García Fernández, José M ^g   Ohno, Kousaku ^b,h  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c UNIVERSITY OF SEVILLE   (Spain)

^d GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^e MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^f TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^g INSTITUTO DE INVESTIGACIONES QUÍMICAS   (Spain)

^h SAN IN ROSAI HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXYGALACTONOJIRIMYCIN ARYLTHIOUREA DERIVATIVE; 4 PHENYLBUTYRIC ACID; ALPHA GALACTOSIDASE; ASPARTIC ACID; BECLIN 1; CELASTROL; CHAPERONE; GLOBOTRIAOSYLCERAMIDE; THIOUREA DERIVATIVE; UNCLASSIFIED DRUG; 1 DEOXYNOJIRIMYCIN; CERAMIDE TRIHEXOSIDE; MIGALASTAT; THIOUREA;

ARTICLE; AUTOPHAGY; CATALYSIS; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME STABILITY; FABRY DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROGEN BOND; IN VITRO STUDY; LIGAND BINDING; LIPOPHILICITY; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; UPREGULATION; X RAY CRYSTALLOGRAPHY; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; DRUG EFFECTS; ENZYMOLOGY; FIBROBLAST; GENETICS; METABOLISM; MOLECULAR DOCKING; MUTATION; PATHOLOGY; PROTEIN TRANSPORT;

1-DEOXYNOJIRIMYCIN; ALPHA-GALACTOSIDASE; ANIMALS; AUTOPHAGY; CERCOPITHECUS AETHIOPS; COS CELLS; CRYSTALLOGRAPHY, X-RAY; ENZYME STABILITY; FABRY DISEASE; FIBROBLASTS; HUMANS; MOLECULAR DOCKING SIMULATION; MUTATION; PROTEIN TRANSPORT; THIOUREA; TRIHEXOSYLCERAMIDES;

EID: 84904555816     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb500143h     Document Type: Article

References (49)

1. Brady, R., Gal, A. E., Bradley, R. M., Marternsson, E., Warshaw, A. L., and Laster, L. (1967) Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency N. Eng. J. Med. 276, 1163-1167
2. Desnick, R. J., Ioannou, Y. A., and Eng, C. M. (2001) Galactosidase A deficiency: Fabry disease. In The Metabolic and Molecular Bases of Inherited Disease (Scriver, C. R., Beaudet, A. L., Sly, W. S., and Valle, D., Ed.), pp 3733-3774, McGraw-Hill, New York.
3. Metha, A., Ricci, R., Widmer, U., Dehout, D., Garcia de Lorenzo, A., Kampmann, C., Linhart, A., Suncer-Plassmann, G., Ries, M., and Beck, M. (2004) Fabry disease defined baseline clinical manifestations of 366 patients in the Fabry Outcome Survey Eur. J. Clin. Invest. 34, 236-242 (Pubitemid 38406640)
4. Chévrier, M., Brakch, N., Céline, L., Genty, D., Ramdani, Y., Moll, S., Djavaheri-Mergny, M., Brasse-Lagnel, C., Annie Laquerrière, A. L., Barbey, F., and Bekri, S. (2010) Autophagosome maturation is impaired in Fabry disease Autophagy 6, 589-599
5. Spada, M., Pagliardini, S., Yasuda, M., Tukel, T., Thiagarajan, G., Sakuraba, H., Ponzone, A., and Desnick, R. J. (2006) High incidence of later-onset Fabry disease revealed by newborn screening Am. J. Hum. Genet. 79, 31-40 (Pubitemid 43927374)
6. Hwu, W. L., Chien, Y. H., Lee, N. C., Chiang, S. C., Dobrovolny, R., Huang, A. C., Yeh, H. Y., Chao, M. C., Lin, S. J., Kitagawa, T., Desnick, R. J., and Hsu, L. W. (2009) Newborn screening for Fabry disease by measuring GLA activity using tandem mass spectrometry Hum. Mutat. 30, 1397-1405
7. Lieberman, R. L., D'aquino, J. A., Ringe, D., and Petsko, G. A. (2009) Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability Biochemistry 48, 4816-4827
8. Guce, A. I., Clark, N. E., Salgado, E. N., Ivanen, D. R., Kulminskaya, A. A., Brumer, H., 3rd, and Garman, S. C. (2010) Catalytic mechanism of human α-galactosidase J. Biol. Chem. 285, 3625-3632
9. Garman, S. C. (2007) Structure-function relationship in α-galactosidase A Acta Paediatr. Suppl. 96, 6-16
10. Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., and Desnick, R. J. (2001) Safety and efficacy of recombinant human α-galactosidase A. replacement therapy in Fabry's disease N. Eng. J. Med. 345, 9-16 (Pubitemid 32634266)
11. Schiffmann, R., Kopp, J. B., Austin, H. A., 3rd, Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E., and Brady, R. O. (2001) Enzyme replacement therapy in Fabry disease: A randomized controlled trial JAMA 285, 2743-2749 (Pubitemid 32525371)
12. Bénichou, B., Goyal, S., Sung, C., Norfleet, A. M., and O'Brien, F. (2009) A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on the efficacy during enzyme replacement therapy for Fabry disease Mol. Genet. Metab. 96, 4-12
13. Boyd, R. E., Lee, G., Rybczynski, P., Benjamin, E. R., Khanna, R., Wustman, B. A., and Valenzano, K. J. (2013) Pharmacological chaperones as therapeutics for lysosomal storage diseases J. Med. Chem. 56, 2705-2725
14. Higaki, K., Ninomiya, H., Suzuki, Y., and Nanba, E. (2013) Candidate molecules for chemical chaperone therapy of GM1-gangliosidosis Future Med. Chem. 5, 1551-1558
15. Fan, J. Q., Ishii, S., Asano, N., and Suzuki, Y. (1999) Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor Nat. Med. 5, 112-115 (Pubitemid 29051008)
16. Wu, X., Katz, E., Della Valle, M. C., Mascioli, K., Flanagan, J. J., Castelli, J. P., Schiffmann, R., Boudes, P., Lockhart, D. J., Valenzano, K. J., and Benjamin, E. R. (2011) A pharmacogenic approach to identify mutant forms of α-galactosidase A that respond to a pharmacological chaperone for Fabry disease Hum. Mutat. 32, 965-977
17. Khanna, R., Soska, R., Lun, Y., Feng, J., Frascella, M., Young, B., Brignol, N., Pellegrino, L., Sitaraman, S. A., Desnick, R. J., Benjamin, E. R., Lockhart, D. J., and Valenzano, K. J. (2010) The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease Mol. Ther. 18, 23-33
18. Germain, D. P., Giugliani, R., Hughes, D. A., Mehta, A., Nicholls, K., Barisoni, L., Jennette, C. J., Bragat, A., Castelli, J., Sitaraman, S., Lockhart, D. J., and Boudes, P. F. (2012) Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: Report from two phase 2 clinical studies Orphanet J. Rare Dis. 7, 91
19. Matsuda, J., Suzuki, O., Oshima, A., Yamamoto, Y., Noguchi, A., Takimoto, K., Itoh, M., Matsuzaki, Y., Yasuda, Y., Ogawa, S., Sakata, Y., Nanba, E., Higaki, K., Ogawa, Y., Tominaga, L., Ohno, K., Iwasaki, H., Watanabe, H., Brady, R. O., and Suzuki, Y. (2003) Chemical chaperone therapy for brain pathology in GM1-gangliosidosis Proc. Natl. Acad. Sci. U.S.A. 100, 15912-15917 (Pubitemid 38021089)
20. Takai, T., Higaki, K., Aguilar-Moncayo, M., Mena-Barragán, T., Hirano, Y., Yura, K., Yu, L., Ninomiya, H., García-Moreno, M. I., Sakakibara, Y., Ohno, K., Nanba, E., Ortiz Mellet, C., García Fernández, J. M., and Suzuki, Y. (2013) A bicyclic 1- deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1-gangliosidosis Mol. Ther. 21, 526-532
21. Benjamin, E. R., Khanna, R., Schilling, A., Flanagan, J. J., Pellegrino, L. J., Brignol, N., Lun, Y., Guillen, D., Ranes, B. E., Frascella, M., Soska, R., Feng, J., Dungan, L., Young, B., Lockhart, D. J., and Valenzano, K. J. (2012) Co-administration with the pharmacological chaperone AT1001 increases recombinant human α-galactosidase A tissue uptake and improves substrate reduction in Fabry mice Mol. Ther. 20, 717-726
22. Asano, N., Ishii, S., Kizu, H., Ikeda, K., Yasuda, K., Kato, A., Martin, O. R., and Fan, J. Q. (2000) In vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives Eur. J. Biochem. 267, 4179-4186 (Pubitemid 30436114)
23. Guce, A. I., Clark, N. E., Rogich, J. J., and Garman, S. C. (2011) The molecular basis of pharmacological chaperoning in human α-galactosidase Chem. Biol. 18, 1521-1526
24. Suzuki, Y. (2013) Chaperone therapy update: Fabry disease, GM1-gangliosidosis, and Gaucher disease Brain Dev. 35, 515-523
25. Patnaik, S., Zheng, W., Choi, J. H., Motabar, O., Southall, N., Westbroek, W., Lea, W. A., Velayati, A., Goldin, E., Sidransky, E., Leister, W., and Marugan, J. J. (2012) Discovery, structure-activity relationship, and biological evaluation of noninhibitory small molecule chaperones of glucocerebrosidase J. Med. Chem. 55, 5734-5748
26. Porto, C., Ferrara, M. C., Meli, M., Acampora, E., Avolio, V., Rosa, M., Cobucci-Ponzano, B., Colombo, G., Moracci, M., Andria, G., and Parenti, G. (2012) Pharmacological enhancement of α-glucosidase by the allosteric chaperone N-acetylcysteine Mol. Ther. 20, 2201-2211
27. Legler, G. and Pohl, S. (1986) Synthesis of 5-amino-5-deoxy- d -galactopyranose and 1,5-dideoxy-1,5-imino- d -galactitol, and their inhibition of α- and β- d -galactosidases Carbohydr. Res. 155, 119-129
28. Karelson, M., Kahn, I., and Dobchev, D. A. (2010) Quantitative correlation of physical and chemical properties with chemical structure: Utility for prediction Chem. Rev. 110, 5714-5789
29. Higaki, K., Li, L., Bahrudin, U., Okuzawa, S., Takamura, A., Yamamoto, K., Adachi, K., Paraguison, R. C., Takai, T., Ikehata, H., Tominaga, L., Hisatome, I., Iida, M., Ogawa, S., Matsuda, J., Ninomiya, H., Sakakibara, Y., Ohno, K., Suzuki, Y., and Nanba, E. (2011) Chemical chaperone therapy: Chaperone effect on mutant enzyme and cellular pathophysiology of β-galactosidase deficiency Hum. Mutat. 32, 843-852
30. Aguilar-Moncayo, M., Takai, T., Higaki, K., Mena-Barragán, T., Hirano, Y., Yura, K., Li, L., Yu, Y., Ninomiya, H., García-Moreno, M. I., Ishii, S., Sakakibara, Y., Ohno, K., Nanba, E., Ortiz Mellet, C., García Fernández, J. M., and Suzuki, Y. (2012) Tuning glycosidase inhibition through aglycone interactions: Pharmacological chaperones for Fabry disease and GM1 gangliosidosis Chem. Commun. 48, 6514-6516
31. Butters, T. D., Dwek, R. A., and Platt, F. M. (2005) Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses Glycobiology 15, 42R-52R
32. Settembre, C., Fraldi, A., Rubinsztein, D. C., and Ballabio, A. (2008) Lysosomal storage diseases as disorders of autophagy Autophagy 4, 113-114
33. Filoni, C., Caciotti, A., Carraresi, L., Cavicchi, C., Parini, R., Antuzzi, D., Zampetti, A., Feriozzi, S., Poisetti, P., Garman, S. C., Guerrini, R., Zammarchi, E., Donati, M. A., and Morrone, A. (2010) Functional studies of new GLA gene mutations leading to conformational Fabry disease Biochim. Biophys. Acta 1802, 247-252
34. Siekierska, A., De Baets, G., Reumers, J., Gallardo, R., Rudyak, S., Broersen, K., Couceiro, J., Van Durme, J., Schymkowitz, J., and Rousseau, F. (2012) α-Galactosidase A aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants J. Biol. Chem. 287, 28386-28397
35. Mu, T. W., Ong, D. S., Wang, Y. J., Balch, W. E., Yates, J. R., 3rd, Segatori, L., and Kelly, J. W. (2008) Chemical and biological approaches synergize to ameliorate protein-misfolding disease Cell 134, 769-781
36. Lee, B., Rhead, W., Diaz, G. A., Scharschmidt, B. F., Mian, A., Shchelochkov, O., Marier, J. F., Beliveau, M., Mauney, J., Dickinson, K., Martinez, A., Gargosky, S., Mokhtarani, M., and Berry, S. A. (2010) Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: Safety, pharmacokinetics, and ammonia control Mol. Genet. Metab. 100, 221-228
37. Ammerpohl, O., Trauzold, A., Schniewind, B., Griep, U., Pilarsky, C., Grutzmann, R., Saeger, H. D., Janssen, O., Sipos, B., Kloppel, G., and Kalthoff, H. (2007) Complementary effects on HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells Br. J. Cancer 96, 73-81 (Pubitemid 46094642)
38. Munkacsi, A. B., Chen, F. W., Brinkman, M. A., Higaki, K., Gutiérrez, G. D., Chaudhari, J., Layer, J. V., Tong, A., Bard, M., Boone, C., Ioannou, Y. A., and Sturley, S. L. (2011) An "excerbate-reverse" strategy in yeast identifies histon deacetylase inhibitors as a correction for cholesterol and sphingolipid transport defects in human Niemann-Pick type C disease J. Biol. Chem. 286, 23842-23851
39. Lu, J., Yang, C., Chen, M., Ye, D. Y., Lonser, R. R., Brady, R. O., and Zhuang, Z. (2011) Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease Proc. Natl. Acad. Sci. U.S.A. 108, 21200-21205
40. Schitter, G., Scheucher, E., Steiner, A. J., Stütz, A. E., Thonhofer, M., Tarling, C. A., Withers, S. G., Wicki, J., Fantur, K., Paschke, E., Mahuran, D. J., Rigat, B. A., Tropak, M., and Wrodnigg, T. M. (2010) Synthesis of lipophilic 1-deoxygalactonojirimycin derivatives as d -galactosidase inhibitors Beilstein J. Org. Chem. 6, 21
41. Kim, D. W., Uetsuki, T., Kaziro, Y., Yamaguchi, N., and Sugano, S. (1990) Use the human elongation factor 1 α promotor as a versatile and efficient expression system Gene 91, 217-223 (Pubitemid 20269505)
42. Ishii, S., Chang, H. H., Kawasaki, K., Yasuda, K., Wu, H. L., Garman, S. C., and Fan, J. Q. (2007) Mutant α-galactosidase A enzymes identified in Fabry patients with residual enzyme activity: Biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin Biochem. J. 406, 285-295 (Pubitemid 47310959)
43. Brumshtein, B., Aguilar-Moncayo, M., Benito, J. M., García Fernández, J. M., Silman, I., Shaaltiel, Y., Aviezer, D., Sussman, J. L., Futerman, A. H., and Ortiz Mellet, C. (2011) Cyclodextrin-mediated crystallization of acid β-glucosidase in complex with amphiphilic bicyclic nojirimycin analogues Org. Biomol. Chem. 9, 4160-4167
44. Otwinowski, Z. and Minor, W. (1997) Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 276, 307-326 (Pubitemid 27085611)
45. McCoy, A., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., and Read, R. J. (2007) Phaser crystallographic software J. Appl. Crystallogr. 40, 658-674 (Pubitemid 47080256)
46. Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. (2010) PHENIX: A comprehensive Python-based system for macromolecular structure solution Acta Crystallogr. D Biol. Crystallogr. 66, 213-221
47. Emsley, P. and Cowtan, K. (2004) Coot: Model-building tools for molecular graphics Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (Pubitemid 41742764)
48. Moriarty, N. W., Grosse-Kunstleve, R. W., and Adams, P. D. (2009) Electronic Ligand Builder and Optimization Workbench (eLBOW): A tool for ligand coordinate and restraint generation Acta Crystallogr. D Biol. Crystallogr. 65, 1074-1080
49. Schuttelkopf, A. W. and van Aalten, D. M. (2004) PRODRG: A tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr. D Biol. Crystallogr. 60, 1355-63 (Pubitemid 41079731)